⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Immune System Key Ltd. (ISK) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Immune System Key Ltd. (ISK)
↗Jerusalem, Israel
Immune System Key (ISK) Ltd. is a privately held, clinical-stage biotechnology company focused on the discovery and development of innovative treatments for malignant and autoimmune diseases. The company's therapeutic assets are based on novel human secreted peptides discovered by its founders.
ISK's flagship candidate, Nerofe (dTCApFs), is a peptide derivative designed to act through a novel mechanism involving the T1/ST2 receptor. The company is exploring Nerofe's potential in various oncology indications, including Acute Myeloid Leukemia (AML), pancreatic cancer, and metastatic colorectal cancer, often in combination with other agents to modulate the tumor microenvironment.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2005
Ownership:private
Status:operating
FUNDING
Stage:Grant-funded
Total Raised:$2.5M (approx. in grants)
Investors:Israel Innovation Authority
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2a
Modalities:Peptide
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Georgetown University (Clinical trials), Johnson & Johnson Innovation – JLABS (Resident company)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, Kite Pharma
LEADERSHIP
Key Executives:
Yoram Devary - Co-Founder & CTO
Uziel Sandler - Co-Founder
Scientific Founders:Uziel Sandler, Yoram Devary
LINKS
Website:immunesk.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Immune System Key Ltd. (ISK). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.